Finding the right dose: antifungal drug studied in sickest ICU patients
NCT ID NCT04868188
First seen Jan 07, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study looked at 32 adults in the ICU on ECMO life support who had severe influenza or COVID-19 and a fungal lung infection called aspergillosis. Researchers measured how the antifungal drug voriconazole behaves in the body to find the best dose for these very sick patients. The goal was to improve treatment and reduce side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospitals of Leicester
Leicester, United Kingdom
Conditions
Explore the condition pages connected to this study.